# US 2009/0269397 A1 · Targeted and high density drug loaded polymeric materials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269397 A1
- Document ID: US20090269397A1
- Status: Published application
- Kind: A1
- Application number: 12/467,819
- Filed: 2009-05-18
- Published: 2009-10-29
- Earliest claimed: 2004-07-01
- Assignees: Yale University
- Inventors: William Mark Saltzman; Tarek Fahmy; Peter Fong
- Web page: https://patentgrep.com/patent/US20090269397A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other fields. Targeted polymeric microparticles have also been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.

## Claims

### Claim 1

Polymeric microparticles for delivery of a therapeutic, nutritional, diagnostic or prophylactic agent incorporated in a high density on or within the microparticles, the microparticles comprising ligands present in a density of between about which is preferably in the range of 1,000 to 10,000,000, more preferably 10,000-1,000.000, ligands per square micron of microparticle surface area.

### Claim 2 (depends on 1)

The microparticles of claim 1 wherein the ligands have a first end incorporated into the surface of the microparticle and a second end facing outwardly from the surface of the microparticle.

### Claim 3 (depends on 2)

The microparticles of claim 2 wherein the polymer is a hydrophobic polymer and the ligands are materials with an HLB of less than 10, more preferably less than 5, which insert into the surface of the microparticles.

### Claim 4 (depends on 3)

The microparticles of claim 3 comprising a hydrophobic polymer having fatty acid conjugates inserted therein and extending outwardly from the polymeric surface.

### Claim 5 (depends on 1)

The microparticles of claim 1 wherein the ligands are, or are bound to, an agent to be delivered selected from the group consisting of therapeutic, nutritional, diagnostic, and prophylactic agents, attachment molecules, targeting molecules, and mixtures thereof.

### Claim 6 (depends on 5)

The microparticles of claim 5 having bound thereto targeting molecules.

### Claim 7 (depends on 6)

The microparticles of claim 6 wherein the targeting molecules are physically or chemically attached to the ligands.

### Claim 8 (depends on 5)

The microparticles of claim 5 further comprising agent encapsulated within the polymer.

### Claim 9 (depends on 8)

The microparticles of claim 8 for delivery of the same or different agents in the form of a two phase delivery or pulsed delivery.

### Claim 10 (depends on 5)

The microparticles of claim 5 wherein targeting molecules are bound to the surface of the microparticles or to the ligands.

### Claim 11 (depends on 10)

The microparticles of claim 10 wherein the targeting molecules are selected from the group consisting of specific targeting molecules and non-specific targeting molecules.

### Claim 12 (depends on 10)

The microparticles of claim 10 wherein the density and means of attachment, whether covalent or ionic, direct or via the means of linkers, of the ligands is used to modulate targeting of the microparticles.

### Claim 13 (depends on 10)

The microparticles of claim 10 wherein the targeting molecules are selected from the group consisting of antibodies and fragments thereof, sugars, peptides, and ligands for cell surface receptors.

### Claim 14 (depends on 5)

The microparticles of claim 5 wherein the ligands are attachment molecules.

### Claim 15 (depends on 14)

The microparticles of claim 14 wherein the ligand is, or is bound to, an attachment molecule selected from the group consisting of strepavidin and biotin.

### Claim 16 (depends on 1)

The microparticles of claim 1 further comprising linkers attached to the ligands.

### Claim 17 (depends on 16)

The microparticles of claim 16 wherein the linkers are branched and multiple agents to be delivered or attachment molecules are attached via the linkers to each of the ligands.

### Claim 18 (depends on 16)

The microparticles of claim 16 wherein the linkers are polyethyleneglycol star polymers.

### Claim 19 (depends on 5)

The microparticles of claim 5 wherein the agent to be delivered is a therapeutic or nutritional agent selected from the group consisting of drugs, proteins, peptides, sugars, polysaccharides, nucleotide molecules, and nucleic acid molecules.

### Claim 20 (depends on 5)

The microparticles of claim 5 wherein the agent to be delivered is a diagnostic agent selected from the group consisting of paramagnetic molecules, fluorescent compound, magnetic molecules, and radionuclides,

### Claim 21 (depends on 18)

The microparticles of claim 18 wherein the agent to be delivered inhibits calcification.

### Claim 22 (depends on 5)

The microparticles of claim 5 wherein the agent to be delivered is a cytotoxic or antiproliferative agent.

### Claim 23 (depends on 5)

The microparticles of claim 5 wherein the linkers are polyethyleneglycol and the attachment molecules are strepavidin, avidin or biotin.

### Claim 24 (depends on 1)

The microparticles of claim 1 having a diameter that is between 0.5 and 20 microns.

### Claim 25 (depends on 1)

The microparticles of claim 1 in the form of nanoparticles having a diameter between 50 and 500 nanometers.

### Claim 26 (depends on 25)

The microparticles of claim 25 wherein the nanoparticles have a diameter of less than 100 nm.

### Claim 27 (depends on 1)

The microparticles of claim 1 encapsulated in a liposome.

### Claim 28

A method for making a microparticle for delivery of a therapeutic, nutritional, diagnostic or prophylactic agent comprising
Providing a solution of a hydrophobic polymer or the polymer in liquid form,
Adding materials with an HLB of less than 10, more preferably less than 5, to the polymer, which insert into the surface of the microparticles when the polymer is solidified to form microparticles under conditions wherein one end of the material with an HLB of less than 10 inserts into the polymer and the other extends outwardly from the polymeric surface of the microparticle.

### Claim 29 (depends on 28)

The method of claim 28 wherein the hydrophobic polymer and material with an HLB of less than 10 is added to the polymer in a water in oil in water emulsion.

### Claim 30 (depends on 28)

The method of claim 28 wherein the material with an HLB of less than 10 is first conjugated to a targeting or attachment molecule or therapeutic, prophylactic or diagnostic agent.

### Claim 31 (depends on 28)

The method of claim 28 wherein the material with an HLB of less than 10 is a fatty acid, lipid or detergent.

### Claim 32

Microparticles formed of a hydrophobic or lipophilic polymer with a first end of a material with an HLB of less than 10 as a ligand interspersed therein and a second end of the material with an HLB of less than 10 facing outwardly from the surface of the microparticles.

### Claim 33 (depends on 32)

The microparticles of claim 32 wherein material with an HLB of less than 10 is selected from the group consisting of fatty acids, lipids and detergents.
